Sponsor:
Amgen
Code:
NCT06700343
Conditions
Relapsing-remitting Multiple Sclerosis (RRMS)
Eligibility Criteria
Sex: All
Age: 18 - 60
Healthy Volunteers: Not accepted
Interventions
Ocrelizumab (US)
Ocrelizumab (EU)
ABP 692
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-18. This information was provided to ClinicalTrials.gov by Amgen on 2025-04-04.